Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
2019 · The Lancet Oncology · 549 citations
https://doi.org/10.1016/s1470-2045(19)30328-6
U
Udai Banerji
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
645
Papers
12.1K
Citations
52
h-index
142
i10-index
Udai Banerji is an academic researcher from Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & PI3K/AKT/mTOR signaling in cancer & Cancer Genomics and Diagnostics. The author has an h-index of 52, co-authored 549 publications.
ORCID: 0000-0003-1503-3123Papers by this author
worksAntibody-drug conjugates—an emerging class of cancer treatment
2016 · British Journal of Cancer · 509 citations
https://doi.org/10.1038/bjc.2015.435
Maximising the potential of AKT inhibitors as anti-cancer treatments
2016 · Pharmacology & Therapeutics · 224 citations
https://doi.org/10.1016/j.pharmthera.2016.12.001
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
2020 · Nature Communications · 126 citations
https://doi.org/10.1038/s41467-020-15596-z
The kinase polypharmacology landscape of clinical PARP inhibitors
2020 · Scientific Reports · 114 citations
https://doi.org/10.1038/s41598-020-59074-4
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
2009 · British Journal of Cancer · 98 citations
https://doi.org/10.1038/sj.bjc.6605030
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat